To analyze the role of M-receptor subtypes in the forearm resistance vasculature of normotensive volunteers (n=20), we infused acetylcholine (ACh) and methacholine (MCh) Animal and in vitro studies have shown that Mlreceptors are present on sympathetic ganglia, where they inhibit the release of norepinephrine.8 Central M,-receptors can also be found in the hippocampus and cerebral cortex.9 In the heart, M2-receptors reduce contractility and heart rate (HR) and induce contraction of the coronary arteries.3 Activation of M3-receptor subtypes, which are present in glandular tissue and the intestine, causes an increase in secretion and contraction of smooth muscle.'0 In several vascular beds, M3-receptors have been shown to induce endotheliumdependent vasodilatation, a process that, at least in part, is dependent on the release of endothelium-
T he recent discovery of selective antagonists of muscarinic (M)-receptors has greatly facilitated the research on cholinergic vascular responses. M-receptors are divided in three pharmacologically functional subtypes, namely, Ml, M2, and M3 (for reviews, see References 1 through 3). In addition, the existence of a fourth subtype (M4) has recently been submitted. [4] [5] [6] By means of molecular biologic cloning techniques, five molecular subtypes (m1 through M5) have been identified and analyzed. Three of these cloned subtypes (M1, M2, and M3) correspond to the functional receptors M1, M2, and M3, whereas the functional relevance of the M4 and Mi structures remains to be established.7
Animal and in vitro studies have shown that Mlreceptors are present on sympathetic ganglia, where they inhibit the release of norepinephrine.8 Central M,-receptors can also be found in the hippocampus and cerebral cortex. 9 In the heart, M2-receptors reduce contractility and heart rate (HR) and induce contraction of the coronary arteries.3 Activation of M3-receptor subtypes, which are present in glandular tissue and the intestine, causes an increase in secretion and contraction of smooth muscle.'0 In several vascular beds, M3- receptors have been shown to induce endotheliumdependent vasodilatation, a process that, at least in part, is dependent on the release of endothelium-M2>M1>M3) displays a certain degree of cardioselectivity and is assumed to be selective for the M2-receptor subtype.14 Moderate selectivity for the M3-receptor subtype, which is known to occur in certain types of vascular smooth muscle, has been submitted for experimental compounds such as 4-diphenylacetoxy-N-methylpiperidine methobromide (4-DAMP)34"1 and p-fluorohexahydrosiladifenydol (p-FHHSiD).'0
The M3-receptor subtype has been demonstrate.d in vitro in several types of large conduit arteries of different animal species10 and has been shown to mediate vasodilatation, presumably via the release of EDRF (NO). In addition, Hendriks et al16 have recently shown that the M3-receptor subtype is also present in rat mesenteric resistance arteries and is responsible for the cholinergic vasodilator response. Its characteristics are the same in resistance vessels and conduit arteries. 16 In the resistance vessels of the human forearm, the L-arginine/NO pathway has been shown to be responsible, at least in part, for the vasodilator response to acetylcholine (ACh).1718
Until now, little evidence has been presented concerning the character and functionality of M-receptor subtypes in human resistance vasculature. For this reason, we analyzed the M-receptor subtypes mediating cholinergic vasodilatation in resistance vessels of the human forearm. Accordingly, we established the influence of various competitive antagonists, such as atropine, pirenzepine, and AF-DX 116, on the vasodilatation induced by methacholine (MCh). The pharmacodynamic effects were quantified as concentration-response curves (CRCs), and for the first time, in humans and in vivo we applied the Schild analysis19 to characterize the role of M-receptor subtypes involved in cholinergic vasodilatation.
Subjects and Methods Subjects
The present study was undertaken in 20 healthy male volunteers (mean age, 24 years; range, 19 to 31 years). Their medical history, physical examination, and routine laboratory tests did not show any abnormalities.
Twelve hours before the study, the subjects refrained from smoking, alcohol, and caffeine-containing beverages. The protocol was approved by the medical ethics committee of the Leiden University Hospital, and informed consent was obtained from all subjects.
Procedures
All experiments were performed in a quiet room kept at 22°C to 24°C. During the experiments, the subjects were in the supine position with both forearms stabilized slightly above the level of the heart. After local anesthesia of the skin with 1% lignocaine, the brachial artery of the nondominant arm was cannulated in the cubital fossa. The cannula (Autocath 1453.13, Plastimed, Saint-Leu-la-Foret, France) was used for infusion of drugs with a constant-rate infusion pump Baseline values were recorded during 3 minutes before each experiment. The average values of FBF, FVR, HR, and intraarterial BP, obtained from six consecutive recordings during the last 1.5 minutes of each infusion step, were used for analysis.
In the present study we investigated the potencies of the M-receptor antagonists pirenzepine (Ml) and AF-DX 116 (M2) in three different groups of normotensive volunteers.
Atropine, a nonselective M-receptor antagonist, was used for comparison.
Group I
We constructed a dose-response curve (DRC) for the effects of the endogenous M-receptor agonist ACh (1 to 1000 ng* kg`1 minm1 intra-arterially). Subsequently, we constructed a DRC for MCh (0.1 to 100 ng* kg`min`intra-arterially), which is known to be a more stable compound in plasma, since it is much less susceptible to degradation by cholinesterase. The control infusion with MCh was given twice in succession to validate the length of the "washout interval" of the agonist used. Subsequently, we repeated the DRCs with MCh (dose range, 0.1 to 1000 ng kg`. min-1 intra-arterially) in the presence of continuous-dose infusions of the nonselective M-receptor antagonist atropine (0.6, 6, and 60 ng * kg 1 min-1 intra-arterially).
Group II
We investigated the potency of the M1-receptor antagonist pirenzepine by constructing DRCs for MCh (dose range, 0.1 to 1000 ng* kg -min`intra-arterially) in the presence of vehicle (control) and with continuous-dose infusions of pirenzepine (8, 80 , and 800 ng * kg`min1 intra-arterially). The experiments were always performed with increasing doses of antagonist to prevent "carryover" effects between the experiments. We repeated the infusion with MCh in the presence of vehicle after the experiments with antagonists to exclude possible time-dependent variations.
Group III
The potency of the M2-receptor antagonist AF-DX 116 (80, 800, and 8000 ng . kg`1 min`intra-arterially) was assessed in a manner similar to that in group II (see Fig 1) . Again, two control DRCs with MCh were constructed, one before the experiments with the antagonist and one at the end of the day, at least 60 minutes after the last experiment with AF-DX 116.
Calculations
The average of six consecutive FBF measurements, made in the last 1.5 minutes of each dose step, was used for further analysis. Plasma concentrations (Cplasma, in micromoles per liter) of the drugs infused were calculated from the rate of drug infusion (IR, Table 4 ). The slope of the regression line was not significantly different from unity, thus indicating competitive antagonism (see Table 4 and Fig 4) . The baseline hemodynamic characteristics were determined at least 45 minutes after the cannulation of the brachial artery and before the first experiment. During this period, the subjects were at rest and remained in the supine position. (8, 80 , and 800 ng* kg-'. min1 intra-arterially; group II) caused a shift to the right of the CRCs for the MCh-induced vasodilatation without affecting the maximal vasodilator response (Fig 3) . Pirenzepine (calculated plasma concentrations, 0.1 to 10 ,umol/L) was less potent than atropine, with an apparent pA2 value of 6.71±0.08 (7.07±0.09 after correcting for the increase in FBF; see Table 4 ), and a slope of the regression line not different from unity (Table 4 and Fig 4) . Cumulative-Dose Infusions of MCh in the Presence of AF-DX 116 AF-DX 116 (80, 800, and 8000 ng * kg`1 min-1 intraarterially; group III), a cardioselective compound known to display preference for M2-receptors, proved to be the weakest competitive antagonist of MCh-mediated vasodilatation (calculated plasma concentrations, 1 to 100 ,mol/L; Fig 3) . Schild regression analysis yielded a pA2 value of 5.32±0.05 (5.65 ±0.07 after correcting for the increase in FBF) with a slope that did not differ from unity (Table 4 and Fig 4) .
None of the M-receptor antagonists used in the present investigations caused any changes in FBF or FVR. Accordingly, the rank order of potency for the three M-receptor antagonists used appears to be atropine>pirenzepine>AF-DX 116 (see Table 4 ).
The progressive steepening of the CRCs can be explained by the fact that the plasma concentration of the antagonist, which is infused in a fixed dose, is Antagonists with a certain degree of selectivity have been frequently used to characterize M-receptors, and they are more useful for this purpose than M-receptor agonists, those available being rather unselective. In vitro studies have shown that the affinities of the nonselective agonists ACh and MCh for M-receptors are similar.10 In the present investigation, however, we found that ACh is -10-fold less potent than is MCh. We presume that this is the result of the rapid degradation of ACh by cholinesterase present in plasma. Therefore, we used MCh as the reference M-receptor agonist in the present study.
The EC5, values found for MCh were practically equal for the three groups of normotensive volunteers investigated (Table 3) , which confirms the value of this agonist as a pharmacologic tool. In addition, the EC,0 values The rank order of potency (atropine>pirenzepine> AF-DX 116) and the low affinities of pirenzepine and AF-DX 116 that we observed suggest that it is predominantly the M3-receptor that triggers vasodilatation.
Since a functional role for the M4-and m5-receptor subtypes has as yet not been established, the involvement of the M3-receptor can only be postulated by inference. For ethical reasons, we could not perform human experiments with the few and moderately selective M3-receptor antagonists available (p-FHHSiD and 4-DAMP).
Cholinergic vasodilatation can be mediated by presynaptic inhibition of norepinephrine release from sympathetic nerve endings (M,-receptor mediated8) and by activation of the L-arginine/NO pathway (M3-receptor mediated10). Since our data indicate that an important role for the M,-receptor is unlikely, it seems reasonable to assume that the vasodilator response is mainly medi-ated by M3-receptors, probably by stimulating the L-arginine/NO pathway. The fact that none of the M-receptor antagonists used caused a change in FBF or FVR suggests that at rest there is no basal cholinergic tone present in the vascular bed of the forearm. The apparent pA2 values mentioned should not be interpreted as an absolute measure for receptor affinity and can only be considered as an estimate of the relative potencies of the compounds used.
To our knowledge, a functional role for M-receptor subtypes mediating vasodilatation in response to infused cholinergic agonists in the forearm has not yet been demonstrated. Moreover, characterization of the M-receptor subtype mediating cholinergic vasodilatation by use of competitive antagonists and Schild analysis in an in vivo human experimental system is novel. Cholinergic vasodilatation in this vascular bed is mediated primarily by the M3-receptor subtype.
